Editas Medicine CMO becomes reporting insider

Editas Medicine’s EVP and Chief Medical Officer filed an initial Form 3 reporting no transactions or listed holdings.

Rhea-AI Filing Summary

Editas Medicine, Inc. (EDIT) had its EVP, Chief Medical Officer, Daniel Scott Ory, file an initial statement of beneficial ownership on Form 3. The filing reports no equity transactions and does not list any specific holdings or derivative positions for him as of the filing date.

Key Figures

Reported purchase transactions: 0 transactions Reported sale transactions: 0 transactions Net shares bought or sold: 0 shares

3 metrics

Reported purchase transactions 0 transactions Buy transaction count in the Form 3 transaction summary for Daniel Scott Ory

Reported sale transactions 0 transactions Sell transaction count in the Form 3 transaction summary for Daniel Scott Ory

Net shares bought or sold 0 shares Net buy/sell share total in the Form 3 transaction summary

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the new Form 3 filing mean for Editas Medicine (EDIT)?

The Form 3 indicates that Daniel Scott Ory, EVP and Chief Medical Officer of Editas Medicine, has become a reporting insider. The filing reports no equity transactions and does not disclose any specific share or option holdings in this statement.

Who is the insider named in this Editas Medicine (EDIT) Form 3?

The insider is Daniel Scott Ory, who serves as EVP, Chief Medical Officer of Editas Medicine, Inc. The Form 3 establishes him as a reporting person under SEC rules.

Does the Editas Medicine (EDIT) Form 3 show any stock purchases or sales?

No. The Form 3 for Editas Medicine’s EVP, Chief Medical Officer reports no buy or sell transactions. All transaction counts, including purchases, sales, and derivative exercises, are shown as zero.

Are any stock or option holdings disclosed for the Editas Medicine (EDIT) insider on this Form 3?

No. The summary data for this Form 3 shows no reported holdings of common stock or derivative securities, and there are no holding entries listed for Daniel Scott Ory in this filing.

Is there any Rule 10b5-1 trading plan noted in this Editas Medicine (EDIT) Form 3?

No. The Form 3 does not indicate that transactions were made under a Rule 10b5-1 trading plan, and there are no transactions reported in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 04:25 PM Accepted by SEC EDGAR 09/09/2026 - 04:24 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ory Daniel Scott

(Last) (First) (Middle)

C/O EDITAS MEDICINE, INC.

11 HURLEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/08/2026

3. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

No securities are beneficially owned.

	/s/ Daniel Ory, M.D.	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)